Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial-There is No Significant Reduction in Death (Yet)

被引：7
|
作者：
Michels, Jorg [1 ]
机构：
[1] Torbay Hosp, Torquay, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 01期
关键词：
D O I：
10.1200/JCO.2016.67.4630
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：123 / +
页数：2
相关论文
共 50 条
  • [1] Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial-There is No Significant Reduction in Death (Yet) Reply
    Penson, David F.
    Armstrong, Andrew J.
    Concepcion, Raoul
    Agarwal, Neeraj
    Olsson, Carl
    Karsh, Lawrence
    Dunshee, Curtis
    Wang, Fong
    Wu, Kenneth
    Krivoshik, Andrew
    Phung, De
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01)
  • [2] Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
    Penson, David F.
    Armstrong, Andrew J.
    Concepcion, Raoul
    Agarwal, Neeraj
    Olsson, Carl
    Karsh, Lawrence
    Dunshee, Curtis
    Wang, Fong
    Wu, Kenneth
    Krivoshik, Andrew
    Phung, De
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18) : 2098 - +
  • [3] Re: Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
    Kimura, Takahiro
    Egawa, Shin
    EUROPEAN UROLOGY, 2017, 71 (02) : 303 - 303
  • [4] Re: Enzalutamide versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2016, 196 (03): : 741 - 741
  • [5] Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
    Penson, David F.
    Armstrong, Andrew J.
    Concepcion, Raoul S.
    Agarwal, Neeraj
    Olsson, Carl A.
    Karsh, Lawrence, I
    Dunshee, Curtis J.
    Duggan, William
    Shen, Qi
    Sugg, Jennifer
    Haas, Gabriel P.
    Higano, Celestia S.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2022, 25 (02) : 363 - 365
  • [6] Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
    David F. Penson
    Andrew J. Armstrong
    Raoul S. Concepcion
    Neeraj Agarwal
    Carl A. Olsson
    Lawrence I. Karsh
    Curtis J. Dunshee
    William Duggan
    Qi Shen
    Jennifer Sugg
    Gabriel P. Haas
    Celestia S. Higano
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 363 - 365
  • [7] Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
    David F. Penson
    Andrew J. Armstrong
    Raoul S. Concepcion
    Neeraj Agarwal
    Carl A. Olsson
    Lawrence I. Karsh
    Curtis J. Dunshee
    William Duggan
    Qi Shen
    Jennifer Sugg
    Gabriel P. Haas
    Celestia S. Higano
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 597 - 597
  • [8] EFFICACY AND SAFETY OF ENZALUTAMIDE VERSUS BICALUTAMIDE IN YOUNGER AND OLDER PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN THE TERRAIN TRIAL
    Siemens, D. Robert
    Klotz, Laurence
    Heidenreich, Axel
    Chowdhury, Simon
    Villers, Arnauld
    Baron, Benoit
    Van Os, Steve
    Hasabou, Nahla
    Brown, Scott
    Wang, Fong
    Forer, David
    Shore, Neal D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 117 - 117
  • [9] Enzalutamide in Castration-Resistant Prostate Cancer
    Bregni, Giacomo
    Rebuzzi, Sara E.
    Fornarini, Giuseppe
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (14): : 1380 - 1381
  • [10] Enzalutamide in castration-resistant prostate cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2014, 15 (08): : E312 - E312
12345